文献速递关节外科骨质疏松与代谢性骨病

GLP-1受体激动剂与全髋/膝关节置换术后90天结局改善相关:系统综述与荟萃分析

Glucagon-like peptide-1 receptor agonists are associated with improved 90-day outcomes after total hip and knee arthroplasty : a systematic review and meta-analysis.
PubMed 文献 · Bone Joint J · 2026-08-01

结果显示GLP-1a组90天手术并发症(RR 0.73)、内科并发症(RR 0.78)和再入院率(RR 0.79)均较低,THA亚组关联更强。

要点

  • GLP-1a组90天手术并发症合并RR为0.73,THA亚组RR为0.63。
  • GLP-1a组90天再入院率RR为0.79,THA亚组RR为0.82,TKA亚组RR为0.77。
  • 除医疗费用证据等级为中等外,其余结局GRADE证据置信度均极低。

核心结论

  • GLP-1a治疗可能降低高危糖尿病和肥胖患者THA与TKA术后90天手术并发症、内科并发症及再入院率。
  • GLP-1a的使用还可能带来显著的医疗费用节省。

研究设计与样本

  • 纳入研究中GLP-1a均用于管理2型糖尿病或肥胖患者减重,患者平均年龄61.9岁,女性占60.1%(n=57,939)。

主要发现

  • GLP-1a组90天手术并发症合并风险比(RR)为0.73。
  • GLP-1a组90天内科并发症RR为0.78,90天再入院率RR为0.79(I²=61.6%)。
  • 两年翻修率在GLP-1a组为1.7%至3.3%,对照组为1.7%至4.5%。
  • THA亚组中GLP-1a与90天手术并发症(RR 0.63)、内科并发症(RR 0.55)和再入院(RR 0.82)显著降低相关。
  • TKA亚组中GLP-1a仅与90天再入院率降低显著相关(RR 0.77)。

关键数值与推荐

  • 90天手术并发症定义为假体周围关节感染(PJI)、伤口裂开、假体周围骨折(PPF)、血肿、神经损伤或手术部位感染(SSI)。
  • 两项研究总体偏倚风险为严重,八项为中等;除医疗费用(中等)外,其余结局GRADE证据置信度均为极低。

临床怎么用

  • 对于合并2型糖尿病或肥胖的高危患者,在THA或TKA术前使用GLP-1a可能有助于减少90天手术及内科并发症和再入院。
  • THA患者中GLP-1a的关联更强,TKA患者中仅再入院率降低显著,临床决策需结合关节类型个体化评估。

局限性

  • 纳入研究均为匹配队列研究,两项存在严重总体偏倚风险,八项为中等风险。
  • 除医疗费用外,所有结局的GRADE证据置信度均为极低。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIMS: Obesity and diabetes are risk factors for developing osteoarthritis and associated with worse outcomes following total hip (THA) and total knee arthroplasty (TKA). Glucagon-like peptide-1 receptor agonists (GLP-1as) improve glycaemic control and promote weight loss. The aim of this study was to assess the impact of GLP-1a treatment on 90-day surgical complications following THA and TKA. METHODS: A systematic review was undertaken according to PRISMA guidelines. Studies were included if they reported at least one outcome of interest following primary THA or TKA. In all the studies which were included, a GLP-1a was prescribed for the management of type 2 diabetes mellitus or for weight loss in obese patients. The primary outcome was the 90-day surgical complication rate in the combined THA and TKA cohort. The 90-day surgical complications were defined as: periprosthetic joint infection (PJI), wound dehiscence, periprosthetic fracture (PPF), haematoma, nerve injury, or surgical site infection (SSI). Secondary outcomes included 90-day medical complications and readmission rates, all-cause revision, healthcare costs, and length of stay. RESULTS: A total of 78 studies were reviewed, and ten matched cohort studies with a total of 96,356 patients (30,350 THAs and 66,606 TKAs) were included. The mean age of the patients was 61.9 years; 60.1% female (n = 57,939). Two studies had a serious risk of overall bias and eight had a moderate risk. The confidence of evidence according to the GRADE assessment was very low for all but one outcome measure (healthcare cost: moderate). The rate of 90-day surgical complications was lower in the GLP-1a cohort (pooled risk ratio (RR) 0.73). The use of a GLP-1a lowered the 90-day medical complications and readmission rates (RR 0.78 and RR 0.79 (I2 = 61.6%), respectively). At two years, the revision rate ranged from 1.7% to 3.3% for the GLP-1a cohort and 1.7% to 4.5% for the controls. Sub-group analysis showed a stronger association in the THA group, in which the use of a GLP-1a was associated with significantly lower rates of 90-day surgical complications (RR 0.63), 90-day medical complications (RR 0.55), and 90-day readmissions (RR 0.82). In contrast, the use of a GLP-1a in the TKA group was only sigificantly associated with a lower 90-day readmission rate (RR 0.77). CONCLUSION: GLP-1a treatment before THA and TKA potentially reduces the 90-day surgical and medical complications and 90-day readmission rates in high-risk diabetic and obese patients. The use of a GLP-1a may also be associated with substantial cost savings.

来源:Bone Joint J,查看原文。版权归原作者所有。

引用

  1. Rudran B, Little CDJ, Palmer AJR, et al. Glucagon-like peptide-1 receptor agonists are associated with improved 90-day outcomes after total hip and knee arthroplasty : a systematic review and meta-analysis. Bone Joint J. 2026. PMID: 42538001. doi:10.1302/0301-620X.108B8.BJJ-2025-1486.R2

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。